KRAS and rectal cancer: In a previously published work we have shown the valid assessment of KRAS mutation status for therapeutic decisions in pre-therapeutic (treatment naïve) biopsies as well as in post-therapeutic (after preoperative CRT) residual tumor tissue in patients with locally advanced rectal cancer [12].